President & CEO of Ocular Therapeutix Inc (OCUL, Financial) Antony C. Mattessich bought 40,000 shares of OCUL on 06/06/2019 at an average price of $2.81 a share. The total cost of this purchase was $112,400.
Ocular Therapeutix Inc is a biopharmaceutical company. It is engaged in developing and commercializing therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix Inc has a market cap of $139.210 million; its shares were traded at around $3.25 with and P/S ratio of 61.37. Ocular Therapeutix Inc had annual average EBITDA growth of 15.30% over the past five years.
CEO Recent Trades:
- President & CEO Antony C. Mattessich bought 40,000 shares of OCUL stock on 06/06/2019 at the average price of $2.81. The price of the stock has increased by 15.66% since.
Directors and Officers Recent Trades:
- Chairman of the Board Amarpreet Sawhney bought 124,468 shares of OCUL stock on 06/07/2019 at the average price of $2.92. The price of the stock has increased by 11.3% since.
- Chairman of the Board Amarpreet Sawhney bought 45,780 shares of OCUL stock on 06/05/2019 at the average price of $2.91. The price of the stock has increased by 11.68% since.
- Chief Medical Officer Michael H. Goldstein bought 12,000 shares of OCUL stock on 05/28/2019 at the average price of $2.51. The price of the stock has increased by 29.48% since.
For the complete insider trading history of OCUL, click here
.
